IL1B and atherosclerosis: Although IL1β has been extensively studied and an antibody against this cytokine proved to be effective in attenuating atherosclerosis in a mouse model, the CANTOS trial showed as minimal as 15% reduction in the primary endpoint with an IL1β antibody (canakinumab) in a phase III clinical trial (4, 5, 119).